Data set for pathology reporting of cutaneous invasive melanoma: Recommendations from the international collaboration on cancer reporting (ICCR)

American Journal of Surgical Pathology

Volumn 37, Issue 12, 2013, Pages 1797-1814

  Scolyer, Richard A ^a,b,c   Judge, Meagan J ^d   Evans, Alan ^e   Frishberg, David P ^f   Prieto, Victor G ^g   Thompson, John F ^a,b,c   Trotter, Martin J ^h   Walsh, Maureen Y ⁱ   Walsh, Noreen M G ^j   Ellis, David W ^k  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d Quality Assurance Programs   (Australia)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ ROYAL VICTORIA HOSPITAL   (United Kingdom)

^j DALHOUSIE UNIVERSITY   (Canada)

^k FLINDERS UNIVERSITY   (Australia)

more..

Author keywords

checklist; diagnosis; melanoma; pathology; protocol; quality; reporting; staging; synoptic report; treatment

Indexed keywords

ARTICLE; HUMAN; MELANOMA; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; SKIN TUMOR; STANDARD;

HUMANS; MELANOMA; PATHOLOGY, CLINICAL; RESEARCH DESIGN; SKIN NEOPLASMS;

EID: 84888133379     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31829d7f35     Document Type: Article

References (142)

1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374:362-365
2. Thompson JF, Scolyer RA, Kefford RF. Melanoma - A management guide for GPs. Aust Fam Physician. 2012;41:470-473
3. Scolyer RA, Prieto VG. Melanoma pathology: Important issues for clinicians involved in the multidisciplinary care of melanoma patients. Surg Oncol Clin N Am. 2011;20:19-37
4. Australian Cancer Network Melanoma Guidelines Revision Working Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand: Cancer Council Australia and Australian Cancer Network. Wellington: Sydney and New Zealand Guidelines Group; 2008
5. Lankshear S, Srigley J, McGowan T, et al. Standardized synoptic cancer pathology reports: So what and who cares? A populationbased satisfaction survey of 970 pathologists, surgeons, and oncologists. Arch Pathol Lab Med. 2013. In press
6. Karim RZ, Van Den Berg KS, Colman MH, et al. The advantage of using a synoptic pathology report format for cutaneous melanoma. Histopathology. 2008;52:130-138
7. Protocol for the examination of specimens from patients with melanoma of the skin. College of American Pathologists, 2011. Available at: Http://www.cap.org/apps/docs/committees/cancer/ cancer-protocols/2011/ SkinMelanoma-11protocol.pdf. Accessed December 1, 2011
8. Primary cutaneous melanoma structured reporting protocol (1st edition 2010). Royal College of Pathologists of Australasia, 2010. Available at: Http://www.rcpa.edu.au//static/File/Asset%20library/ public%20documents/ Publications/StructuredReporting/PRIMA RY%20CUTANEOUS%20MELANOMA%20STRUCTURED% 20REPORTING%20PROTOCOL.pdf. Accessed December 1, 2011
9. Minimum dataset for the histopathological reporting of common skin cancers. Royal College of Pathologists, 2002. Available at: Http://www.rcpath. org/index.asp?PageID=254. Accessed December 1, 2011
10. McCluggage WG, Colgan T, Duggan M, et al. Data set for reporting of endometrial carcinomas: Recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia. Int J Gynecol Pathol. 2013;32:45-65
11. Kench JG, Delahunt B, Griffiths DF, et al. Dataset for reporting of prostate carcinoma in radical prostatectomy specimens: Recommendations from the International Collaboration on Cancer Reporting. Histopathology. 2013;62:203-218
12. Merlin T, Weston A, Tooher R. Extending an evidence hierarchy to include topics other than treatment: Revising the Australian 'levels of evidence'. BMC Med Res Methodol. 2009;9:34
13. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-1576
14. Barnhill RL, Katzen J, Spatz A, et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol. 2005;32:268-273
15. Gimotty P, Elder D, Fraker D, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134
16. Ostmeier H, Fuchs B, Otto F, et al. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanomä Cancer. 1999;85:2391-2399
17. Scolyer RA, Thompson JF, Stretch Jr. Pathology of melanocytic lesions: New, controversial, and clinically important issues. J Surg Oncol. 2004;86:200-211
18. Scolyer RA, Mihm MC Jr, Cochran AJ, et al. Pathology of melanoma. In: Balch CM, Houghton A Jr, Sober A, Soong SJ, eds. Cutaneous Melanoma. 5th ed. St Louis, MO: Quality Medical Publishing; 2009:205-248
19. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. Analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498
20. Balch CM, Murad TM, Soong SJ. A multifactorial analysis of melanoma: Prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg. 1978;188:732-742
21. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634
22. Tan KB, Moncrieff M, Thompson JF, et al. Subungual melanoma: A study of 124 cases highlighting features of early lesions, potential pitfalls in diagnosis, and guidelines for histologic reporting. Am J Surg Pathol. 2007;31:1902-1912
23. Scolyer RA, Crotty KA, Palmer AA, et al. Pagetoid spread of melanocytes in Spitz naevi: Authors' reply. Pathology. 2002;34:591
24. Tan K-B, Murali R, Thompson JF, et al. Current perspectives on the pathologic diagnosis and reporting of melanocytic tumors. Ital J Dermatol Venereol. 2007;142:83-97
25. Ng JC, Swain S, Dowling JP, et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: Experience of an Australian tertiary referral service. Arch Dermatol. 2010;146:234-239
26. Scolyer RA, Thompson JF, McCarthy SW, et al. Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis. Australas J Dermatol. 2006;47:71-73
27. Scolyer RA, McCarthy SW, Elder DE. Frontiers in melanocytic pathology. Pathology. 2004;36:385-386
28. Armour K, Mann S, Lee S. Dysplastic naevi: To shave, or not to shave? A retrospective study of the use of the shave biopsy technique in the initial management of dysplastic naevi. Australas J Dermatol. 2005;46:70-75
29. Dymock RB, Menz J. Recurrent melanocytic naevi following partial removal (pseudomelanoma). Australas J Dermatol. 1986;27:67-69
30. Kornberg R, Ackerman AB. Pseudomelanoma: Recurrent melanocytic nevus following partial surgical removal. Arch Dermatol. 1975;111:1588-1590
31. Suster S. Pseudomelanoma. A pathologist's perspective. Int J Dermatol. 1986;25:506-507
32. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908
33. Edge SE, Byrd DR, Compton CC, et al. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010
34. Thompson JF, Ollila DW. Optimum excision margins for melanoma. Lancet. 2011;378:1608-1610
35. Pasquali S, Haydu LE, Scolyer RA, et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. Ann Surg. 2013;258:152-157
36. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Database Syst Rev. 2009;CD004835
37. Heenan PJ. Local recurrence of melanoma. Pathology. 2004; 36:491-495
38. Veronesi U, Cascinelli N. Narrow excision (1-cm margin)-a safe procedure for thin cutaneous melanoma. Arch Surg. 1992;126: 438-441
39. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer. 2000;89:1495-1501
40. Balch CM, Soong S, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol. 2001;8:101-108
41. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick) - Long-term results of a large European multicentric phase III study. Cancer. 2003;97:1941-1946
42. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med. 2004;350: 757-766
43. Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer. 2010;46:270-283
44. Marsden JR, Newton-Bishop JA, Burrows L, et al. Revised U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol. 2010;163:238-256
45. Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Cancer Netw. 2009;7:250-275
46. Shiau CJ, Thompson JF, Scolyer RA. Controversies and evolving concepts in the diagnosis, classification and management of lentigo maligna. Expert Rev Dermatol. 2013;8:195-214
47. AJCC (American Joint Committee on Cancer). AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2009
48. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648
49. AJCC (American Joint Committee on Cancer). AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002
50. Retsas S, Henry K, Mohammed MQ, et al. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): Validation in a cohort of 1284 patients. Eur J Cancer. 2002;38:511-516
51. Gimotty P, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056
52. Nagore E, Oliver V, Botella-Estrada R, et al. Prognostic factors in localized invasive cutaneous melanoma: High value of mitotic rate, vascular invasion and microscopic satellitosis. Melanoma Res. 2005;15:169-177
53. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426-433
54. Clark W Jr, Elder D, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893-1904
55. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29:2199-2205
56. Scolyer RA, Thompson JF. Mitotic rate in melanoma should be recorded as the number of mitoses per mm2 (not per high power field): Surgeons tell your pathologists! Am J Surg. 2013. In press
57. Yun SJ, Gimotty PA, Hwang WT, et al. High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma. Am J Surg Pathol. 2011;35:235-242
58. Xu X, Chen L, Guerry D, et al. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res. 2012;18:229-237
59. Schmoeckel C, Bockelbrink A, Bockelbrink H, et al. Low- and high-risk malignant melanoma. I. Evaluation of clinical and histological prognosticators in 585 cases. Eur J Cancer Clin Oncol. 1983;19:227-235
60. Kashani-Sabet M, Sagebiel RW, Ferreira CM, et al. Vascular involvement in the prognosis of primary cutaneous melanoma. Arch Dermatol. 2001;137:1169-1173
61. Petersson F, Diwan AH, Ivan D, et al. Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol. 2009;36:1157-1163
62. Smithers BM, McLeod GR, Little JH. Desmoplastic, neural transforming and neurotropic melanoma: A review of 45 cases. Aust N Z J Surg. 1990;60:967-972
63. Carlson JA, Dickersin GR, Sober AJ, et al. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer. 1995;75:478-494
64. McCarthy SW, Crotty KA, Scolyer RA. Desmoplastic melanoma and desmoplastic neurotropic melanoma. In: LeBoit PE, Burg G, Weedon D, Sarasian A, eds. World Health Organization Classification of Tumors Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006:76-78
65. Pasquali S, van der Ploeg AP, Mocellin S, et al. Lymphatic biomarkers in primary melanomas as predictors of regional lymph node metastasis and patient outcomes. Pigment Cell Melanoma Res. 2013;26:326-337
66. Baer SC, Schultz D, Synnestvedt M, et al. Desmoplasia and neurotropism. Prognostic variables in patients with stage I melanoma. Cancer. 1995;76:2242-2247
67. Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma: A study of 252 patients. Cancer. 2010; 116:4130-4138
68. Sassen S, Shaw HM, Colman MH, et al. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: Analysis of 2303 melanoma patients treated at a single center. Ann Surg Oncol. 2008;15:630-637
69. Chen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: A clinicopathologic analysis of 128 cases. Cancer. 2008;113:2770-2778
70. Harrist TJ, Rigel DS, Day CLJ, et al. 'Microscopic satellites' are more highly associated with regional lymph node metastases than is primary melanoma thickness. Cancer. 1984;53:2183-2187
71. Leó n P, Daly JM, Synnestvedt M, et al. The prognostic implications of microscopic satellites in patients with clinical stage I melanoma. Arch Surg. 1991;126:1461-1468
72. Day CL Jr, Harrist TJ, Gorstein F, et al. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat. Ann Surg. 2001;194:108-112
73. Shaikh L, Sagebiel RW, Ferreira CM, et al. The role of microsatellites as a prognostic factor in primary malignant melanoma. Arch Dermatol. 2005;141:739-742
74. Scolyer RA, Thompson JF. Desmoplastic melanoma: A heterogeneous entity in which subclassification as "pure" or "mixed" may have important prognostic significance. Ann Surg Oncol. 2005;12:197-199
75. Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: Experience with 280 patients. Cancer. 1998;83:1128-1135
76. Jain S, Allen PW. Desmoplastic malignant melanoma and its variants. A study of 45 cases. Am J Surg Pathol. 1989;13:358-373
77. Busam K, Mujumdar U, Hummer A, et al. Cutaneous desmoplastic melanoma: Reappraisal of morphologic heterogeneity and prognostic factors. Am J Surg Pathol. 2004;28:1518-1525
78. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: A pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol. 2005;12:207-213
79. Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. Ann Surg Oncol. 2003;10:403-407
80. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006;106:900-906
81. Arora A, Lowe L, Su L, et al. Wide excision without radiation for desmoplastic melanoma. Cancer. 2005;104:1462-1467
82. Shaw HM, Quinn MJ, Scolyer RA, et al. Survival in patients with desmoplastic melanoma. J Clin Oncol. 2006;24:E12-E13
83. Busam KJ. Cutaneous desmoplastic melanoma. Adv Anat Pathol. 2005;12:92-102
84. McCarthy S, Scolyer R, Palmer A. Desmoplastic melanoma: A diagnostic trap for the unwary. Pathology. 2004;36:445-451
85. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade (TIL grade) is an independent predictor of sentinel lymph node status and survival in cutaneous melanoma patients. J Clin Oncol. 2012;30:2678-2683
86. Chakera AH, Hesse B, Burak Z, et al. EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging. 2009;36:1713-1742
87. Scolyer RA, Murali R, McCarthy SW, et al. Pathologic examination of sentinel lymph nodes from melanoma patients. Semin Diagn Pathol. 2008;25:100-111
88. Scolyer RA, Murali R, Satzger I, et al. The detection and significance of melanoma micrometastases in sentinel nodes. Surg Oncol. 2008;17:165-174
89. Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol. 2004;31:357-362
90. Carson KF, Wen DR, Li PX, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol. 1996;20:834-840
91. Messina JL, Glass LF, Cruse CW, et al. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol. 1999;23:686-690
92. Li LX, Scolyer RA, Ka VS, et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence: A clinicopathologic study of 1152 patients undergoing sentinel lymph node biopsy. Am J Surg Pathol. 2003;27:1197-1202
93. Itakura E, Huang RR, Wen DR, et al. "Stealth" melanoma cells in histology-negative sentinel lymph nodes. Am J Surg Pathol. 2011; 35:1657-1665
94. Yan S, Brennick JB. False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes. Am J Surg Pathol. 2004;28:596-600
95. Barnhill RL. Malignant melanoma. In: Barnhill RL, Piepkorn M, Busam KJ, eds. Pathology of Melanocytic Nevi and Malignant Melanoma. 2nd ed. New York: Springer Publishing; 2004:238-356
96. Massi D, LeBoit PE. Patterns of melanoma in situ. In: Massi G, LeBoit PE, eds. Histological Diagnosis of Nevi and Melanoma. Wurzburg, Germany: Steinkopff Verlag Darmstadt; 2004:413-429
97. Weyers W, Euler M, Diaz-Cascajo C, et al. Classification of cutaneous malignant melanoma: A reassessment of histopathologic criteria for the distinction of different types. Cancer. 1999;86: 288-299
98. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol. 2011;5:124-136
99. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147
100. Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003;95:806-812
101. Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980; 45:3012-3017
102. Grande Sarpa H, Reinke K, Shaikh L, et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. Am J Surg Pathol. 2006;30:1396-1400
103. t Hout FEM, Haydu LE, Murali R, et al. Prognostic importance of the extent of ulceration in clinically localized cutaneous melanoma. Ann Surg. 2012;255:1165-1170
104. Kelly J, Sagebiel R, Clyman S, et al. Thin level IV malignant melanoma - A subset in which level is the major prognostic indicator. Ann Surg. 1985;202:98-103
105. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303-1310
106. Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74:43-47
107. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869-875
108. Cook MG, Spatz A, Brocker EB, et al. Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group. J Pathol. 2002;197:188-193
109. McCarthy SW, Scolyer RA. Pitfalls and important issues in the pathologic diagnosis of melanocytic tumors. Ochsner J. 2010;10:66-74
110. Kunte C, Geimer T, Baumert J, et al. Analysis of predictive factors for the outcome of complete lymph node dissection in melanoma patients with metastatic sentinel lymph nodes. J Am Acad Dermatol. 2011;64:655-662. quiz 37
111. Murali R, Desilva C, Thompson JF, et al. Factors predicting recurrence and survival in sentinel lymph node-positive melanoma patients. Ann Surg. 2011;253:1155-1164
112. Ariyan C, Brady MS, Gonen M, et al. Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16:186-190
113. van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008; 248:949-955
114. Francischetto T, Spector N, Neto Rezende JF, et al. Influence of sentinel lymph node tumor burden on survival in melanoma. Ann Surg Oncol. 2010;17:1152-1158
115. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17: 747-755
116. Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004;22:3345-3349
117. Wiener M, Acland KM, Shaw HM, et al. Sentinel node positive melanoma patients: Prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model. Ann Surg Oncol. 2010;17:1995-2005
118. Younan R, Bougrine A, Watters K, et al. Validation study of the s classification for melanoma patients with positive sentinel nodes: The Montreal experience. Ann Surg Oncol. 2010;17:1414-1421
119. Starz H, Balda BR, Kramer KU, et al. A micromorphometrybased concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91:2110-2121
120. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol. 2011;29:2206-2214
121. Murali R, Desilva C, Thompson JF, et al. Non-Sentinel Node Risk Score (N-SNORE): A scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28:4441-4449
122. Cadili A, Scolyer RA, Brown PT, et al. Total sentinel lymph node tumor size predicts nonsentinel node metastasis and survival in patients with melanoma. Ann Surg Oncol. 2010;17:3015-3020
123. Scolyer RA, Li LX, McCarthy SW, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol. 2004;122:532-539
124. Murali R, Cochran AJ, Cook MG, et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: Implications for management of patients with melanoma. Cancer. 2009;115:5026-5037
125. Scolyer RA, Thompson JF, Stretch JR, et al. Collaboration between clinicians and pathologists: A necessity for the optimal management of melanoma patients. Cancer Forum. 2005;29:76-81
126. Haydu LE, Holt PE, Karim RZ, et al. Quality of histopathological reporting on melanoma and influence of use of a synoptic template. Histopathology. 2010;56:768-774
127. Messenger DE, McLeod RS, Kirsch R. What impact has the introduction of a synoptic report for rectal cancer had on reporting outcomes for specialist gastrointestinal and nongastrointestinal pathologists? Arch Pathol Lab Med. 2011;135:1471-1475
128. Scolyer RA, Murali R, McCarthy SW, et al. Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: Approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. Arch Pathol Lab Med. 2010;134:1770-1777
129. Zembowicz A, Scolyer RA. Nevus/melanocytoma/melanoma: An emerging paradigm for classification of melanocytic neoplasms? Arch Pathol Lab Med. 2011;135:300-306
130. Ladstein RG, Bachmann IM, Straume O, et al. Tumor necrosis is a prognostic factor in thick cutaneous melanoma. Am J Surg Pathol. 2012;10:1477-1482
131. Scolyer RA, Thompson JF. Biospecimen banking: The pathway to personalized medicine for patients with cancer. J Surg Oncol. 2013;107:681-682
132. Bastian BC. Molecular cytogenetics as a diagnostic tool for typing melanocytic tumors. Recent Results Cancer Res. 2002;160: 92-99
133. Gerami P, Wass A, Mafee M, et al. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol. 2009;33:1783-1788
134. Pouryazdanparast P, Newman M, Mafee M, et al. Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am J Surg Pathol. 2009;33:1396-1400
135. Newman MD, Lertsburapa T, Mirzabeigi M, et al. Fluorescence in situ hybridization as a tool for microstaging in malignant melanoma. Mod Pathol. 2009;22:989-995
136. Gerami P, Mafee M, Lurtsbarapa T, et al. Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol. 2010;146:273-278
137. Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol. 2009;33: 1146-1156
138. Morey AL, Murali R, McCarthy SW, et al. Diagnosis of cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology. 2009;41:383-387
139. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600- mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366:707-714
140. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367:1694-1703
141. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516
142. International Collaboration on Cancer Reporting: Pathology Reporting Datasets. 2013. Available at: Http://www.rcpa.edu.au/ Publications/ StructuredReporting/ICCR-CANCER-DATASETS. htm. Accessed March 15, 2013